Notably, heightened expression of RAC3 has been identified in BLCA tissues that exhibit drug resistance, where it is implicated in augmenting chemoresistance through the PAK1-ERK1/2 signaling pathway (44). The gene discussed is RAC3; the disease is bladder transitional cell carcinoma.